KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $391.0 million.

  • Pacira BioSciences' Other Operating Expenses fell 77.54% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.6 million, marking a year-over-year decrease of 48.48%. This contributed to the annual value of $391.0 million for FY2024, which is 61.58% up from last year.
  • Per Pacira BioSciences' latest filing, its Other Operating Expenses stood at $391.0 million for FY2024, which was up 61.58% from $242.0 million recorded in FY2023.
  • Over the past 5 years, Pacira BioSciences' Other Operating Expenses peaked at $391.0 million during FY2024, and registered a low of $130.4 million during FY2020.
  • Moreover, its 3-year median value for Other Operating Expenses was $256.6 million (2022), whereas its average is $296.5 million.
  • In the last 5 years, Pacira BioSciences' Other Operating Expenses skyrocketed by 83.82% in 2021 and then fell by 5.70% in 2023.
  • Yearly analysis of 5 years shows Pacira BioSciences' Other Operating Expenses stood at $130.4 million in 2020, then surged by 83.82% to $239.6 million in 2021, then climbed by 7.07% to $256.6 million in 2022, then decreased by 5.70% to $242.0 million in 2023, then surged by 61.58% to $391.0 million in 2024.